Teva Soars as Analysts See More Upside Ahead

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  05 Nov 2025
 

•   TEVA  
   
  +1.35%

After years of watching $TEVA struggle through generic erosion and debt concerns, something feels different this time. TEVA third-quarter results didn't just beat expectations they arrived with the kind of momentum that makes you wonder if we're witnessing an actual turnaround rather than another false dawn.

The numbers tell a story that's hard to ignore. Revenue hit $4.48 billion, crushing forecasts by nearly 6%, while net profit of $910 million exceeded expectations by almost 14%. Leader Capital Markets responded by bumping their price target from $26 to $30 per share, projecting another 25% upside from current levels. For a stock that's already surged 21%, that's not just optimism its conviction backed by fundamental improvement.

What's driving this shift? Start with Austedo, the crown jewel that continues to exceed even management ambitious projections. Teva raised its 2025 revenue guidance for the drug by another $100 million, signaling that peak sales could surpass $3 billion. More importantly, the company expressed high confidence in hitting its 2027 target of over $2.5 billion in Austedo revenue, based on a recently negotiated agreement with CMS under the IRA framework. When a pharmaceutical company with Teva history sounds confident about multi-year forecasts, it's worth paying attention.

The generic business, long considered Teva albatross, showed unexpected strength. Yes, gRevlimid contributed significantly a one-time boost that won't repeat but management projects stability in generic revenues compared to 2024. That's a dramatic change from the consistent declines that defined recent years. Even with some softness in European operations, the stabilization of this segment removes a major overhang that's weighed on the stock for far too long.

Here's what should really catch your attention as an investor: Teva net debt-to-EBITDA ratio dropped below 3x for the first time since 2016. The company expects to end 2025 at approximately 2.8x and reach 2x by 2027. That's not just deleveraging its aggressive balance sheet repair happening faster than anyone anticipated. For those who've watched debt concerns plague this name for years, this trajectory represents a fundamental rerating catalyst.

The biosimilar segment adds another growth dimension. Teva expects to double revenue in this area to roughly $800 million by 2027, driven by expansion in both European and U.S. markets. Meanwhile, the partnership with Sanofi on anti-A1TL advanced to Phase 3 trials in October for both ulcerative colitis and Crohn disease. Teva stands to receive $250 million milestone payments in Q4 2025 and Q1 2026, with potential for hundreds of millions more as the program progresses through additional indications.

The free cash flow story might be the most compelling piece. Management projects over $3.5 billion in free cash flow by 2030, compared to roughly $1.6-1.9 billion this year when including legal settlements. Strip out the one-time legal costs of about $420 million from Q3, and you're looking at a normalized run rate of $2.3-2.5 billion. That trajectory assuming successful execution of efficiency programs and continued deleveraging sets up a company that could return significant capital to shareholders within a few years.

Of course, it won't be a smooth ride. Expect volatility as gRevlimid revenue drops off and efficiency initiatives play out across upcoming quarters. Management acknowledges Q4 profitability will dip from Q3 levels due to gRevlimid effects. But they also project positive EBITDA growth in 2026 despite these headwinds, both in absolute terms and as a percentage of revenue. That's the kind of forward guidance that separates noise from signal.

Leader Capital Markets issued an outperform rating, and it's easy to see why. The combination of deleveraging, cash flow acceleration, and progress in the innovative portfolio paints a picture of sustainable growth rather than another quarterly fluke. $TEVA has burned investors before, and skepticism is warranted. But when debt ratios improve, flagship drugs outperform, and cash flow projections double within five years, the risk-reward equation shifts meaningfully.

For traders and investors who've been waiting for confirmation that Teva turnaround is real rather than rhetorical, this quarter might be that inflection point. The stock has already rewarded believers with a 21% move, but if management delivers on these projections particularly the Austedo trajectory and free cash flow targets there's a legitimate case for the $30 price target and beyond. Sometimes the best moves come when a story that's been written off for years finally starts delivering results that are impossible to ignore.

View All Headlines